CDSCO Panel Approves AstraZeneca's protocol amendment proposal for COPD drug Tozorakimab Dr. Divya Colin19 Aug 2024 5:45 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
AstraZeneca gets USD 107 million Pfizer verdict overturned in US cancer drug patent fight Ruchika Sharma19 Aug 2024 4:45 PM ISTCambridge: AstraZeneca has convinced a Delaware federal judge to throw out a jury's decision that the company owes USD 107.5 million for...
Imfinzi, Lynparza combo approved in EU for mismatch repair proficient advanced or recurrent endometrial cancer: AstraZeneca Ruchika Sharma18 Aug 2024 10:00 AM ISTCambridge: AstraZeneca's Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain...
AstraZeneca Imfinzi in combo with chemotherapy gets USFDA approval for treatment of resectable non-small cell lung cancer before and after surgery Ruchika Sharma17 Aug 2024 1:30 PM ISTCambridge: AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult...
AstraZeneca Imfinzi gets USFDA priority review for limited-stage small cell lung cancer Ruchika Sharma16 Aug 2024 12:30 PM ISTCambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), based on the results from the positive...
50% of trial sites should be Govt sites, more subjects should be enrolled from Govt sites: CDSCO panel tells AstraZeneca on Baxdrostat study Dr. Divya Colin15 Aug 2024 5:45 PM ISTNew Delhi: In line with the drug major AstraZeneca's protocol amendment proposal to study the cardiovascular drug Baxdrostat, the Subject Expert...
AstraZeneca-Daiichi Sankyo Enhertu approved in China for patients with previously treated HER2-positive advanced or metastatic gastric cancer Ruchika Sharma15 Aug 2024 10:30 AM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for...
FDA Advisory Committee reviewed Imfinzi for resectable non-small cell lung cancer based on AEGEAN Phase III trial results Ruchika Sharma28 July 2024 4:15 PM ISTThe Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has acknowledged that AstraZeneca's Imfinzi (durvalumab) met...
AstraZeneca concludes acquisition of Amolyt Pharma Ruchika Sharma17 July 2024 11:30 AM ISTCambridge: AstraZeneca has announced the successful completion of the acquisition of Amolyt Pharma, a clinical-stage biotechnology company...
Pfizer Chief Scientific Officer Dr Mikael Dolsten to depart Ruchika Sharma10 July 2024 2:30 PM ISTNew York: Pfizer Inc. has announced that Dr. Mikael Dolsten, Pfizer's Chief Scientific Officer and President, Pfizer Research & Development,...
AstraZeneca Tagrisso plus chemotherapy approved in EU for EGFR-mutated advanced lung cancer Ruchika Sharma8 July 2024 11:30 AM ISTCambridge: AstraZeneca has announced that Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been...
Lynparza, Imfinzi combo recommended for nod in EU by CHMP for endometrial cancer: AstraZeneca Ruchika Sharma3 July 2024 10:00 AM ISTCambridge: AstraZeneca has announced that Imfinzi (durvalumab) and Lynparza (olaparib) have been recommended for approval in the European Union (EU)...
